Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS toward Phase 2 clinical trials following successful Phase 1 safety and tolerability studies. The company was featured in a BioMedWire editorial highlighting the potential of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (MS). Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy.
Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies and is supported by more than a decade of scientific research. Quantum BioPharma is also advancing a collaboration with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. This imaging tool could provide a more precise way to assess disease progression and treatment efficacy.
The editorial also highlighted developments across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN). These comparisons underscore the competitive landscape in MS research, but Lucid-MS's unique mechanism of action positions it as a potentially transformative therapy.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The company also invented UNBUZZD and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd and receives royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
For more information, visit the company's newsroom at https://ibn.fm/QNTM.
